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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of laparoscopic transperitoneal adrenalectomy versus laparoscopic retroperitoneal adrenalectomy for adrenal tumours
in adults.
B A C K G R O U N D
Description of the condition
Tumours or masses of the adrenal gland are quite common and
usually unilateral. They may originate from the adrenal corticoid
or the adrenal medulla of the gland. They are categorised as ei-
ther functional (hormone-secreting) or silent (non hormone-se-
creting). Moreover, as any tumoural tissue, they may be benign
or malignant. The majority of adrenocortical tumours are benign,
non-functioning adenomas that are discovered incidentally on ab-
dominal imaging studies. This is usually called an adrenal ’inciden-
taloma’. Hormone-secreting adrenocortical tumours are generally
discovered by their symptoms causing Cushing’s syndrome (show-
ing enhanced secretion of adrenocorticotropic hormone, primary
aldosteronism, or much less commonly, virilization. Carcinomas
of the adrenal corticoid are quite rare, but sometimes aggressive.
They may also be functional and cause Cushing’s syndrome, vir-
ilization or both, or be nonfunctional and present as an abdomi-
nal mass or an incidental finding. More rarely tumours arise from
the medulla of the gland. These are called phaeochromocytomas.
Phaeochromocytomas are catecholamine-secreting tumours that
arise from chromaffin cells of the adrenal medulla. They may be
benign or malignant.
Description of the intervention
Adrenalectomy is usually recommended if the adrenal mass is four
cm or greater in diameter, if the mass enlarges by one cm or more
during the period of observation, or if evidence of autonomous
hormonal secretion develops (Young 2007). Open transperitoneal
adrenalectomy has been the gold standard of treatment for adrenal
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disease until 1992, when laparoscopic adrenalectomy was first de-
scribed (Gagner 1992). After induction of anaesthesia, the patient
is placed in lateral decubitus position with the affected side ele-
vated around 60°, usually with the help of a bean bag. The ipsilat-
eral arm is generally supported by a metal L-shaped support that
is secured to the table.
Laparoscopic transperitoneal adrenalectomy (was first described
in 1992 (Gagner 1992). The transperitoneal technique is per-
formed with three to five transperitoneal ports through the ante-
rior abdominal wall. After exposition of the adrenal gland space,
the retroperitoneum is incised and the gland dissected. On the
left side the descending colon is reflected medially, the adrenal
vein is divided with bipolar diathermy or cutting between clips
and dissection is carried out starting just superior to the renal vein
until the adrenal gland is free. On the right side liver retraction
is mandatory, while the colon rarely requires mobilisation. Here,
the peritoneum is incised along the lateral aspect of the inferior
vena cava, down to the superior edge of the renal vein. The short
right adrenal vein is identified and divided between clips. When
then dissection of the gland is completed at the lateral side the
specimen is removed within a bag.
Laparoscopic retroperitoneal adrenalectomy was introduced in
1995 (Mercan 1995). This technique consists of approaching the
adrenal gland directly through the retroperitoneal space, while not
breaching the peritoneum. Patients are placed in lateral decubitus
position and the table flexed in order to expand the operating space
between the 12th rib and the iliac crest. To obtain a retroperitoneal
access a one cm skin incision is made below the 12th rib and a
potential space is created below the fascia by careful finger dis-
section. On the left side the Gerota’s fascia is incised around the
superior aspect of the kidney and dissection is continued medially
along the renal vein, until the main adrenal vein is encountered
and divided between clips until mobilisation is completed. On the
right side, too, the investing fascial layer is opened transversely
along the upper renal pole until the inferior vena cava is identified
to continue dissection superiorly along its lateral edge. Here, the
right adrenal vein is encountered and divided between clips and
the mobilisation of the gland is completed.
Adverse effects of the intervention
Intraoperative bleeding may occur in 1% to 4% of cases, depend-
ing on the different techniques used (Constantinides 2012). Small
liver injuries can occur during retraction or adrenal dissection
on the right, which might be controlled by bipolar coagulation,
simple compression, or placement of fibrin material to achieve
haemostasis, but sometimes, although rarely, may lead to conver-
sion to open surgery. Vascular injuries, especially to the inferior
vena cava, comprise almost 7% of all complications and are the
leading cause for conversion (Corcione 2001). Small injuries may
be compressed and coagulant agents applied. Increasing the intra-
abdominal pressure helps to control bleeding. If bleeding contin-
ues, laparoscopic suturing should be attempted only if the sur-
geon has sufficient experience and skills, otherwise conversion to
open surgery is mandatory. Pleural injuries and pneumothoraces
may occur occasionally, requiring direct diaphragm suture closure
(Naito 1995). A chest tube placement is rarely required initially,
although it may be required later if a significant pneumothorax
develops. Injury to the spleen and the left side of the pancreas are
also reported (Greco 2011; Terachi 2000).
How the intervention might work
Numerous studies have shown the safety and feasibility of the la-
paroscopic technique since its introduction in 1992. Several ben-
efits were shown compared to open procedures: a decreased hospi-
tal stay, faster recovery, decreased pain and narcotic use, and fewer
complications (Assalia 2004).Minimally invasive adrenalectomy is
now considered the standard treatment for benign adrenal masses
(Jacobs 1997). Laparoscopic retroperitoneal adrenalectomy was
first performed and described in 1995 (Mercan 1995). By directly
entering the retroperitoneal space, and not breaching the peri-
toneum, this technique was advocated by the authors potentially
resulting in a shorter operative time, less blood loss, less postopera-
tive pain and shorter hospital stay (Constantinides 2012). Despite
favourable results reported for both minimally invasive adrenalec-
tomy techniques using either the transperitoneal or retroperitoneal
route, only a few studies have compared the two procedures thor-
oughly, showing no superiority of either technique.However,most
studies have been limited by a small sample size and a single-in-
stitution design.
Why it is important to do this review
The intrinsic difficulties of laparoscopic transperitoneal adrenalec-
tomy limited the diffusion of the technique which was performed
in less than 20% of cases until 2006 (Murphy 2010). In the fol-
lowing years, the demonstration of the general advantages of la-
paroscopy, such as reduced blood loss, shorter hospital stay, and
faster return to normal activity (Guazzoni 1995), together with
the accumulated experience inverted the trend in favour of the
laparoscopic technique, so that today laparoscopic transperitoneal
adrenalectomy has become the most widely utilised procedure for
people with benign adrenal disease. Introduced in 1995, laparo-
scopic retroperitoneal adrenalectomy was proposed as a good al-
ternative in selected cases and it was utilised more and more fre-
quently (Mercan 1995). Potential advantages could be a shorter
operative time, less postoperative pain and shorter hospital stay
(Constantinides 2012). Several studies have compared the out-
comes of laparoscopic transperitoneal adrenalectomy and laparo-
scopic retroperitoneal adrenalectomy, but their results are incon-
clusive because of their design and inclusion criteria. In addition,
several meta-analyses have compared the transperitoneal with the
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retroperitoneal adrenalectomy (Chen 2013; Constantinides 2012;
Nigri 2013). These analyses, however, were not fully reliable, be-
cause the number of the included studies and the study popu-
lation were rather small and heterogeneous. Moreover, they pre-
sented a mixture of observational and interventional studies. Fur-
thermore, recent randomised trials could not be included as the
last search conducted was anterior to their publication (Barczy ski
2014; Mohammadi-Fallah 2013). Finally, no sound risk of bias
evaluation was performed. Therefore, our systematic review will
try to establish a reliable body of evidence of relevant outcomes in
people undergoing laparoscopic transperitoneal adrenalectomy or
laparoscopic retroperitoneal adrenalectomy.
O B J E C T I V E S
To assess the effects of laparoscopic transperitoneal adrenalectomy
versus laparoscopic retroperitoneal adrenalectomy for adrenal tu-
mours in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled clinical trials (RCTs).
Types of participants
We will include data from adult (older than 18 years) individ-
uals who underwent laparoscopic transperitoneal adrenalectomy
or laparoscopic retroperitoneal adrenalectomy for preoperatively
assessed adrenal tumours.
Diagnostic criteria
Corticoid and medullary, benign and malignant, functional and
silent tumours or masses of the adrenal gland assessed by both
laboratory and imaging studies.
Types of interventions
We plan to investigate the following comparisons of intervention
versus control/comparator.
• Intervention
◦ Laparoscopic retroperitoneal adrenalectomy defined as
any technique approaching the adrenal gland directly through
the retroperitoneal space, and not breaching the peritoneum.
• Comparator
◦ Laparoscopic transperitoneal adrenalectomy defined as
any technique approaching the adrenal gland directly through
the abdominal wall and peritoneal sac.
Concomitant interventions will have to be the same in the inter-
vention and comparator groups to establish fair comparisons.
Types of outcome measures
Primary outcomes
• All-cause mortality.
• All-cause morbidity.
• Adverse events.
Secondary outcomes
• Operative parameters
◦ Duration of surgery.
◦ Operative blood loss.
◦ Intraoperative bleeding.
◦ Conversion to open surgery.
• Postoperative parameters
◦ Time to oral fluid or food intake.
◦ Time to full ambulation.
◦ Length of hospital stay.
◦ Pneumothorax/haemothorax.
◦ Chest infection/pleural effusion.
◦ Splenic injury.
◦ Abdominal abscess.
• Health-related quality of life.
• Socioeconomic effects.
Method and timing of outcome measurement
• All-cause mortality: defined as death from any cause and
measured within 30 days after surgery and thereafter.
• All-cause morbidity: defined as any deviation from the
regular post-operative course (e.g. chest infection or splenic
injury) and measured within 30 days after surgery and thereafter.
• Adverse events: any undesirable experience happening
during the trial measured within 30 days after surgery and
thereafter..
• Duration of surgery: defined as the duration of general
anaesthesia and measured at the end of general anaesthesia.
• Operative blood loss: defined as the maximum decrease in
haemoglobin and measured at the end of surgery and thereafter.
• Intraoperative bleeding: defined as the occurrence of blood
loss greater than 200 ml and measured at the end of surgery.
• Conversion to open surgery: defined as any technical failure
requiring a larger skin incision before the complete dissection of
the gland and measured at the end of surgery.
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• Time to oral fluid or food intake: defined as the time to oral
intake of fluids or food and measured within one week after
surgery and thereafter.
• Lenght of hospital stay: defined as the time to discharge
from hospital and measured within 30 days after surgery and
thereafter.
• Pneumothorax/haemothorax: defined as any detection of a
collection of air, gas or blood in the chest or pleural space that
causes part or all of a lung to collapse and measured within 30
days after surgery and thereafter.
• Chest infection/pleural effusion: defined as any diagnosis of
infection that affects lungs (either larger or smaller air sacs) or
the accumulation of fluid in the pleural space and measured
within 30 days after surgery and thereafter.
• Splenic injury: defined as any splenic trauma determining
splenic capsule tear or parenchymal hematoma and measured at
the end of surgery and thereafter.
• Health-related quality of life: evaluated by a validated
instrument such as the Short-Form Survey (SF-36) and
measured within the first week, at 30 after surgery and thereafter.
• Socioeconomic effects: such as length of hospital stay, time
to return to normal activity and time to return to work and
measured within 30 days after surgery and thereafter.
’Summary of findings’ table
We will present a ’Summary of findings table’ reporting the fol-
lowing outcomes listed according to priority.
1. All-cause mortality.
2. All-cause morbidity.
3. Adverse events (including some operative or postoperative
parameters).
4. Health-related quality of life.
5. Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We will search the following sources from inception of each
database to the specified date and will place no restrictions on the
language of publication.
• Cochrane Library.
◦ Cochrane Database of Systematic Reviews (CDSR)
◦ Cochrane Central Register of Controlled Trials
(CENTRAL)
◦ Database of Abstracts of Reviews of Effects (DARE)
◦ Health Technology Assessment (HTA)
• MEDLINE.
• EMBASE.
• ClinicalTrials.gov (https://clinicaltrials.gov/).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Protal (http://
apps.who.int/trialsearch/), which is a meta-register of studies
including several trial registers:
◦ Australian New Zealand Clinical Trials Registry
◦ ClinicalTrials.gov
◦ European Union (EU) Clinical Trials Register
◦ International Standard Randomised Controlled Trial
Number (ISRCTN) registry
◦ Brazilian Clinical Trials Registry
◦ Chinese Clinical Trial Registry
◦ Clinical Trials Registry - India
◦ Clinical Research Information Service - Republic of
Korea
◦ Cuban Public Registry of Clinical Trials
◦ German Clinical Trials Register
◦ Iranian Registry of Clinical Trials
◦ Japan Primary Registries Network
◦ Pan African Clinical Trial Registry
◦ Sri Lanka Clinical Trials Registry
◦ The Netherlands National Trial Register
◦ Thai Clinical Trials Register
Wewill continuously apply aMEDLINE (viaOvid SP) email alert
service established by theCochraneMetabolic and Endocrine Dis-
orders (CMED) Group to identify newly published studies using
the same search strategy as described for MEDLINE (for details
on search strategies see Appendix 1). After supplying the final re-
view draft for editorial approval, the CMEDGroup will perform a
complete updated search on all databases available at the editorial
office and send the results to the review authors. Should we iden-
tify new studies for inclusion, we will evaluate these, incorporate
the findings into our review, and resubmit another review draft
(Beller 2013).
If we detect additional relevant key words during any of the elec-
tronic or other searches, wewill modify the electronic search strate-
gies to incorporate these terms and document the changes.
Searching other resources
We will attempt to identify other potentially-eligible trials or an-
cillary publications by searching the reference lists of retrieved in-
cluded trials, (systematic) reviews, meta-analyses and health tech-
nology assessment reports. We will also contact study authors of
included trials in order to identify any further studies that we may
have missed.
Data collection and analysis
Selection of studies
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Two review authors (AA, RC)will independently scan the abstract,
title, or both, of every record retrieved, to determine which studies
should be assessed further. We will investigate all potentially-rele-
vant articles as full text. We will resolve any discrepancies through
consensus or recourse to a third review author (RP). If we cannot
resolve a disagreement, we will add the study as a ’study awaiting
classification’ and we will contact study authors for clarification.
We will present an adapted Preferred Reporting Items for System-
atic Reviews andMeta-Analyses (PRISMA) flow diagram showing
the process of study selection (Liberati 2009).
Data extraction and management
For studies that fulfil inclusion criteria, two review authors (AA,
RC) will independently extract key participant and intervention
characteristics and report data on efficacy outcomes and adverse
events using standard data extraction templates as supplied by the
CMED Group, with any disagreements to be resolved by discus-
sion, or, if required, by consultation with a third review author
(RP).
Wewill provide information including trial identifier about poten-
tially relevant ongoing studies in the ’Characteristics of ongoing
studies’ table and in a joint appendix. We will try to find the pro-
tocol for each included study and will report primary, secondary,
and other outcomes in comparison with data in publications in a
joint appendix ’Matrix of study endpoint (publications and trial
documents)’.
We will email all authors of included studies to enquire whether
they are willing to answer questions regarding their trials. We will
present the results of this survey in an appendix. We will thereafter
seek relevant missing information on the trial from the primary
author(s) of the article, if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary study, we will maximise yield of in-
formation by collating all available data and use themost complete
dataset aggregated across all known publications.
Assessment of risk of bias in included studies
Two review authors (AA, RC) will independently assess the risk of
bias of each included study. We will resolve any disagreements by
consensus, or by consultation with a third review author (RP).
We will use the Cochrane Collaboration’s tool for assessing risk
of bias (Higgins 2011a; Higgins 2011b), and will evaluate the
following criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Imbalances in baseline characteristics (chance bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other potential sources of bias.
Wewill judge the above ’Risk of bias’ criteria as ’low risk’, ’high risk’
or ’unclear risk’ and will evaluate individual bias items as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). We will present a risk of bias graph and a risk of
bias summary.Wewill assess the impact of individual bias domains
on study results at the endpoint and study levels. In case of high
risk of selection bias, we will mark all endpoints investigated in
the associated study as high risk.
We will evaluate whether imbalances in baseline characteristics ex-
isted and how these were addressed (Egbewale 2014; Riley 2013).
For performance bias (blinding of participants and personnel) and
detection bias (blinding of outcome assessors) we will evaluate
the risk of bias separately for each outcome (Hróbjartsson 2013).
We will note whether endpoints were self-reported, investigator-
assessed, or adjudicated outcome measures.
We will consider the implications of missing outcome data from
individual participants per outcome such as high drop-out rates
(e.g. above 15%) or disparate attrition rates (e.g. difference of 10%
or more between study arms).
We will assess outcome reporting bias by integrating the results of
the appendix ’Matrix of study endpoints (publications and trial
documents)’ (Boutron 2014; Mathieu 2009), and the appendix
’Examination of outcome reporting bias’ (Kirkham 2010). This
analysis will form the basis of the judgement of selective reporting
(reporting bias).
We will distinguish between self-reported, investigator-assessed
and adjudicated outcome measures.
We define the following endpoints as self-reported outcomes.
• Adverse events, measured by participants.
• Health-related quality of life.
We define the following endpoints as investigator-assessed out-
comes.
• All-cause mortality
• All-cause morbidity
• Adverse events, measured by study personnel.
• Operative and postoperative parameters.
• Socioeconomic effects.
Measures of treatment effect
We will express dichotomous data as odds ratios (ORs) or risk
ratios (RRs) with 95% confidence intervals (CIs). We will express
continuous data as mean differences (MDs) with 95% CIs. We
will express time-to-event data as hazard ratios (HRs) wit 95%
CIs.
Unit of analysis issues
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We will take into account the level at which randomisation oc-
curred, such as cross-over trials, cluster-randomised trials andmul-
tiple observations for the same outcome.
Dealing with missing data
If possible, we will obtain missing data from study authors, and
carefully evaluate important numerical data such as screened, ran-
domised participants as well as intention-to-treat (ITT), and as-
treated and per-protocol populations. We will investigate attrition
rates, e.g. drop-outs, losses to follow up and withdrawals, and crit-
ically appraise issues of missing data and imputation methods (e.g.
last observation carried forward (LOCF)).
Wheremeans and standard deviations for outcomes have not been
reported and we have not received the needed information from
study authors, we will impute these values by estimating the mean
and variance from the median, range, and the size of the sample
(Hozo 2005), or by assuming the standard deviation of themissing
outcome to be the average of the standard deviations from those
studies where this information was reported.
We will investigate the impact of imputation on meta-analyses by
means of sensitivity analysis.
Assessment of heterogeneity
In the event of substantial clinical, methodological or statistical
heterogeneity, we will not report study results as the pooled effect
estimate in a meta-analysis.
We will identify heterogeneity (inconsistency) through visual in-
spection of the forest plots and by using a standard Chi² test with
a significance level of α = 0.1. In view of the low power of this
test, we will also consider the I² statistic, which quantifies incon-
sistency across studies to assess the impact of heterogeneity on the
meta-analysis (Higgins 2002; Higgins 2003); where an I² statis-
tic of 75% or more indicates a considerable level of heterogeneity
(Higgins 2011a).
When we find heterogeneity, we will attempt to determine pos-
sible reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
If we include 10 or more studies investigating a particular out-
come, we will use funnel plots to assess small-study effects. There
can be several explanations for funnel plot asymmetry, including
true heterogeneity of effect with respect to trial size, poor method-
ological design (and hence bias of small trials), and publication
bias. We will therefore interpret results carefully (Sterne 2011).
Data synthesis
Unless there is good evidence for homogeneous effects across stud-
ies, we will summarise primarily low risk of bias data using a ran-
dom-effects model (Wood 2008). We will interpret random-ef-
fects meta-analyses with due consideration of the whole distribu-
tion of effects, ideally by presenting a prediction interval (Higgins
2009). A prediction interval specifies a predicted range for the true
treatment effect in an individual study (Riley 2011). We will also
perform statistical analyses according to the statistical guidelines
contained in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a).
Quality of evidence
We will present the overall quality of the evidence for each out-
come according to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach which takes
into account issues not only related to internal validity (risk of
bias, inconsistency, imprecision, publication bias) but also to ex-
ternal validity such as directness of results. Two review authors
(AA, RC) will independently rate the quality for each outcome.
We will present a summary of the evidence in a ’Summary of find-
ings’ table, which provides key information about the best esti-
mate of the magnitude of the effect, in relative terms and absolute
differences, for each relevant comparison of alternative manage-
ment strategies, numbers of participants, and studies addressing
each important outcome and the rating of the overall confidence
in effect estimates for each outcome. We will create the ’Summary
of findings’ table based on the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We will present results for the outcomes as described in Types of
outcome measures. If meta-analysis is not possible, we will present
results in a narrative ’Summary of findings’ table .
We will also establish a ’Checklist to aid consistency and repro-
ducibility of GRADE assessments’ to help with standardisation of
’Summary of findings’ tables (Meader 2014).
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity and plan to carry out subgroup analyses with investi-
gation of interactions.
• Tumour size: < 6 cm versus > 6 cm.
• Previous abdominal surgery: yes/no.
• Body mass index (BMI): < 30 kg/m² versus ≥ 30 kg/m².
Sensitivity analysis
We plan to perform sensitivity analyses in order to explore the
influence of the following factors (when applicable) on effect sizes
by restricting the analysis to:
• Published studies.
• Taking into account risk of bias, as specified in the
’Assessment of risk of bias in included studies’ section.
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• Very long or large studies to establish the extent to which
they dominate the results.
• Studies using the following filters: diagnostic criteria,
imputation, language of publication, source of funding (industry
versus other), or country.
We will also test the robustness of the results by repeating the
analysis using different measures of effect size (RRs, ORs etc.)
and different statistical models (fixed-effect and random-effects
models).
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A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library
#1 ((transperiton* or retroperiton* or laparoscop* or endoscop*) near/7 adrenalectom*):ti,ab,kw
#2 [mh “Adrenalectomy”] and [mh “Laparoscopy”]
#3 #1 or #2
MEDLINE (Ovid SP)
1 ((transperiton* or retroperiton* or laparoscop* or endoscop*) adj6 adrenalectom*).tw.
2 Adrenalectomy/ and exp Laparoscopy/
3 1 or 2
4 randomized controlled trial.pt.
5 controlled clinical trial.pt.
6 randomi?ed.ab.
7 placebo.ab.
8 randomly.ab.
9 trial.ab.
10 groups.ab.
11 or/4-10
12 exp animals/ not humans/
13 11 not 12
14 3 and 13
EMBASE (Ovid SP)
1. ((transperiton* or retroperiton* or laparoscop* or endoscop*) adj6 adrenalectom*).tw.
2. random*.tw. or clinical trial*.mp. or exp health care quality/
3. 1 and 2
4. limit 3 to embase
ClinicalTrials.gov (Basic Search)
(transperitoneal OR retroperitoneal OR laparoscopic OR endoscopic OR retroperitoneoscopic) AND (adrenalectomy OR adrenalec-
tomies)
ICTRP Search Portal (Standard Search)
transperiton* AND adrenalectom* OR
retroperiton* AND adrenalectom* OR
laparoscop* AND adrenalectom* OR
endoscop* AND adrenalectom*
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